Menarini Group (Germany)

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

• Economics, Econometrics and Finance 26.7×
• Medicine 1.8×
• Biochemistry, Genetics and Molecular Biology 1.7×

By fractional works in all years, weighted toward what it does more of than the world: Glycemic Control, Insulin Therapy, Cardiovascular Disease, Diabetes, Type 1 Diabetes, Complications, Continuous Glucose Monitoring and Hypoglycemia.

By volume in 2022–2025: Health Systems, Economic Evaluations, Quality of Life, Multiple Myeloma Research and Treatments, Myeloproliferative Neoplasms: Diagnosis and Treatment and Hemophilia Treatment and Research.

1. 1 Health Systems, Economic Evaluations, Quality of Life Economics and Econometrics 0 works
2. 2 Multiple Myeloma Research and Treatments Hematology 0 works
3. 3 Myeloproliferative Neoplasms: Diagnosis and Treatment Genetics 0 works
4. 4 Hemophilia Treatment and Research Hematology 0 works
5. 5 Cancer Treatment and Pharmacology Oncology 0 works
6. 6 Protein Degradation and Inhibitors Molecular Biology 0 works
7. 7 Advanced Breast Cancer Therapies Pulmonary and Respiratory Medicine 0 works
8. 8 Breast Cancer Treatment Studies Cancer Research 0 works
9. 9 Acute Myeloid Leukemia Research Hematology 0 works
10. 10 Amyloidosis: Diagnosis, Treatment, Outcomes Molecular Biology 0 works

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

Output in 2018–2022 was 54% lower than in 2013–2017.

• Freie Universität Berlin
• Technische Universität Berlin
• Humboldt-Universität zu Berlin
• Charité - Universitätsmedizin Berlin
• Fritz Haber Institute of the Max Planck Society
• Federal Institute For Materials Research and Testing
• Fraunhofer Institute for Telecommunications, Heinrich Hertz Institute
• Robert Koch Institute